25.10.2018, 1091 Zeichen

Valneva: Valneva SE, an Austrian/French commercial stage biotech company focused on developing innovative lifesaving vaccines, announced that the European Medicines Agency (EMA) provided positive feedback onthe Company’s general development approach for its Lyme disease vaccine candidate, VLA15. EMA’s comprehensive scientific advice is largely aligned with previous discussions with theUS Food and Drug Administration (FDA) on the strategy for the VLA15 development andreaffirms the Company’s key development assumptions. Wolfgang Bender, Chief Medical Officer of Valneva commented: “Aligning withboth the EMA and FDA bolsters our confidence in the development strategy for our Lyme disease vaccine candidate. We will continue to work very closely with regulatory authorities as we advance our vaccine, with the aim of protecting people from this often debilitatingdisease.” The Company confirms it expects to enter Phase 2 clinical development at the end of 2018.
Valneva: weekly performance: -8.17%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (25/10/2018)

Christian Drastil: Wiener Börse Plausch

Börsepeople im Podcast S16/14: Stefan Scharff

Bildnachweis

Aktien auf dem Radar:Pierer Mobility, UBM, Palfinger, Immofinanz, Addiko Bank, CA Immo, SBO, Porr, Rosenbauer, EuroTeleSites AG, Frequentis, Kostad, Linz Textil Holding, Marinomed Biotech, Wiener Privatbank, Warimpex, Agrana, Amag, EVN, Flughafen Wien, OMV, Österreichische Post, Telekom Austria, Uniqa, VIG, E.ON , BASF, Zalando, Mercedes-Benz Group, Allianz, Hannover Rück.

---